GlassScriptPhysician profile
Gul Khan
NPI 1962894659
$2,116.27
in general payments reported to CMS, 2019-2025
20 companies · $907 in 2025
The $907 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $591 · 2023: $276 · 2024: $24.85 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $698 · Food and Beverage: $432 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $697.90 |
| Food and Beverage | $431.96 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $795.16 | 2021-2025 | |
| Abbvie INC. | $272.25 | 2021-2023 | |
| Amgen INC. | $228.73 | 2021-2023 | Enbrel, Otezla, Tavneos |
| Astrazeneca Pharmaceuticals LP | $144.63 | 2022-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $117.35 | 2023-2025 | Ojjaara, Shingrix, Benlysta |
| Genzyme Corporation | $96.02 | 2021-2025 | |
| Janssen Biotech, INC. | $94.95 | 2023-2025 | Rybrevant, Darzalex |
| Incyte Corporation | $58.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.41 | 2021-2022 | |
| Pfizer INC. | $49.60 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $27.97 | 2022 | |
| Philips North America LLC | $24.58 | 2023 | |
| Celgene Corporation | $23.64 | 2022 | |
| Adaptive Biotechnologies Corporation | $23.37 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.76 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.25 | 2021 | |
| Seagen INC. | $18.36 | 2021 | |
| Scpharmaceuticals INC. | $17.79 | 2025 | |
| Lilly USA, LLC | $15.63 | 2021 | |
| Morphosys, US INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.